Therapeutic Trends in Big Pharma Licensing
In Vivo examines in-licensing deals signed by Big Pharma over the past 12 months by therapeutic category of the product licensed, showing deal count and total committed dollar volume.
You may also be interested in...
South Korea, one of the first countries to be hit by the spread of COVID-19 from China, has implemented new standalone IVD regulations.
A new national security law passed by China is expected to bring an uncertain future to many health companies eyeing a possible listing in Hong Kong.
Gerolymatos International's Sinomarin seawater-based nasal spray is now distributed in France by Laboratoire Gifrer.